-
Something wrong with this record ?
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial
MJB. Taphoorn, L. Dirven, AA. Kanner, G. Lavy-Shahaf, U. Weinberg, S. Taillibert, SA. Toms, J. Honnorat, TC. Chen, J. Sroubek, C. David, A. Idbaih, JC. Easaw, CY. Kim, J. Bruna, AF. Hottinger, Y. Kew, P. Roth, R. Desai, JL. Villano, ED. Kirson,...
Language English Country United States
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
- MeSH
- Chemoradiotherapy adverse effects methods MeSH
- Cytoreduction Surgical Procedures adverse effects methods MeSH
- Adult MeSH
- Glioblastoma epidemiology psychology therapy MeSH
- Combined Modality Therapy MeSH
- Quality of Life * MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Brain Neoplasms epidemiology psychology therapy MeSH
- Follow-Up Studies MeSH
- Neurosurgical Procedures adverse effects methods MeSH
- Disease-Free Survival MeSH
- Transcranial Direct Current Stimulation * adverse effects methods MeSH
- Surveys and Questionnaires MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Physical Therapy Modalities * adverse effects MeSH
- Temozolomide therapeutic use MeSH
- Treatment Outcome MeSH
- Health Status MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
Importance: Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective: To examine the association of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma. Design, Setting, and Participants: This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy. Patients with glioblastoma were randomized 2:1 to combined treatment with TTFields and temozolomide or temozolomide alone. The study was conducted from July 2009 until November 2014, and patients were followed up through December 2016. Interventions: Temozolomide, 150 to 200 mg/m2/d, was given for 5 days during each 28-day cycle. TTFields were delivered continuously via 4 transducer arrays placed on the shaved scalp of patients and were connected to a portable medical device. Main Outcomes and Measures: Primary study end point was progression-free survival; HRQoL was a predefined secondary end point, measured with questionnaires at baseline and every 3 months thereafter. Mean changes from baseline scores were evaluated, as well as scores over time. Deterioration-free survival and time to deterioration were assessed for each of 9 preselected scales and items. Results: Of the 695 patients in the study, 639 (91.9%) completed the baseline HRQoL questionnaire. Of these patients, 437 (68.4%) were men; mean (SD) age, 54.8 (11.5) years. Health-related quality of life did not differ significantly between treatment arms except for itchy skin. Deterioration-free survival was significantly longer with TTFields for global health (4.8 vs 3.3 months; P < .01); physical (5.1 vs 3.7 months; P < .01) and emotional functioning (5.3 vs 3.9 months; P < .01); pain (5.6 vs 3.6 months; P < .01); and leg weakness (5.6 vs 3.9 months; P < .01), likely related to improved progression-free survival. Time to deterioration, reflecting the influence of treatment, did not differ significantly except for itchy skin (TTFields worse; 8.2 vs 14.4 months; P < .001) and pain (TTFields improved; 13.4 vs 12.1 months; P < .01). Role, social, and physical functioning were not affected by TTFields. Conclusions and Relevance: The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays. Trial Registration: clinicaltrials.gov Identifier: NCT00916409.
Department of Medical Oncology Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
Department of Medical Oncology Cross Cancer Institute Edmonton California
Department of Neuro oncology Hospices Civils de Lyon University Claude Bernard Lyon Lyon France
Department of Neurology Hospital Universitari Bellvitge Barcelona Spain
Department of Neurology University of Zurich Zurich Switzerland
Department of Neurosurgery Geisinger Medical Center Danville Pennsylvania
Department of Neurosurgery Lahey Clinic Burlington Massachusetts
Department of Neurosurgery Na Homolce Hospital Prague Czech Republic
Department of Neurosurgery Tel Aviv Medical Center Tel Aviv University Tel Aviv Israel
Department of Neurosurgery University of Southern California Los Angeles
Neurosurgery and Spine Association Maine Medical Center Scarborough Maine
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035419
- 003
- CZ-PrNML
- 005
- 20191014110658.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamaoncol.2017.5082 $2 doi
- 035 __
- $a (PubMed)29392280
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Taphoorn, Martin J B $u Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
- 245 10
- $a Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial / $c MJB. Taphoorn, L. Dirven, AA. Kanner, G. Lavy-Shahaf, U. Weinberg, S. Taillibert, SA. Toms, J. Honnorat, TC. Chen, J. Sroubek, C. David, A. Idbaih, JC. Easaw, CY. Kim, J. Bruna, AF. Hottinger, Y. Kew, P. Roth, R. Desai, JL. Villano, ED. Kirson, Z. Ram, R. Stupp,
- 520 9_
- $a Importance: Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective: To examine the association of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma. Design, Setting, and Participants: This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy. Patients with glioblastoma were randomized 2:1 to combined treatment with TTFields and temozolomide or temozolomide alone. The study was conducted from July 2009 until November 2014, and patients were followed up through December 2016. Interventions: Temozolomide, 150 to 200 mg/m2/d, was given for 5 days during each 28-day cycle. TTFields were delivered continuously via 4 transducer arrays placed on the shaved scalp of patients and were connected to a portable medical device. Main Outcomes and Measures: Primary study end point was progression-free survival; HRQoL was a predefined secondary end point, measured with questionnaires at baseline and every 3 months thereafter. Mean changes from baseline scores were evaluated, as well as scores over time. Deterioration-free survival and time to deterioration were assessed for each of 9 preselected scales and items. Results: Of the 695 patients in the study, 639 (91.9%) completed the baseline HRQoL questionnaire. Of these patients, 437 (68.4%) were men; mean (SD) age, 54.8 (11.5) years. Health-related quality of life did not differ significantly between treatment arms except for itchy skin. Deterioration-free survival was significantly longer with TTFields for global health (4.8 vs 3.3 months; P < .01); physical (5.1 vs 3.7 months; P < .01) and emotional functioning (5.3 vs 3.9 months; P < .01); pain (5.6 vs 3.6 months; P < .01); and leg weakness (5.6 vs 3.9 months; P < .01), likely related to improved progression-free survival. Time to deterioration, reflecting the influence of treatment, did not differ significantly except for itchy skin (TTFields worse; 8.2 vs 14.4 months; P < .001) and pain (TTFields improved; 13.4 vs 12.1 months; P < .01). Role, social, and physical functioning were not affected by TTFields. Conclusions and Relevance: The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays. Trial Registration: clinicaltrials.gov Identifier: NCT00916409.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a nádory mozku $x epidemiologie $x psychologie $x terapie $7 D001932
- 650 _2
- $a chemoradioterapie $x škodlivé účinky $x metody $7 D059248
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a cytoredukční chirurgie $x škodlivé účinky $x metody $7 D065426
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a glioblastom $x epidemiologie $x psychologie $x terapie $7 D005909
- 650 _2
- $a zdravotní stav $7 D006304
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neurochirurgické výkony $x škodlivé účinky $x metody $7 D019635
- 650 12
- $a techniky fyzikální terapie $x škodlivé účinky $7 D026741
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a temozolomid $x terapeutické užití $7 D000077204
- 650 12
- $a přímá transkraniální stimulace mozku $x škodlivé účinky $x metody $7 D065908
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Dirven, Linda $u Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Kanner, Andrew A $u Department of Neurosurgery, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Lavy-Shahaf, Gitit $u Research and Development, Novocure, Haifa, Switzerland.
- 700 1_
- $a Weinberg, Uri $u Research and Development, Novocure, Haifa, Switzerland.
- 700 1_
- $a Taillibert, Sophie $u Department of Neurology 2, Salpêtrière University Hospital, Assistance Public Hôpitaux de Paris, L'Université Pierre et Marie Curie University, Paris VI University, Paris, France.
- 700 1_
- $a Toms, Steven A $u Department of Neurosurgery, Geisinger Medical Center, Danville, Pennsylvania.
- 700 1_
- $a Honnorat, Jerome $u Department of Neuro-oncology, Hospices Civils de Lyon, University Claude Bernard Lyon, Lyon, France.
- 700 1_
- $a Chen, Thomas C $u Department of Neurosurgery, University of Southern California, Los Angeles.
- 700 1_
- $a Sroubek, Jan $u Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.
- 700 1_
- $a David, Carlos $u Department of Neurosurgery, Lahey Clinic, Burlington, Massachusetts.
- 700 1_
- $a Idbaih, Ahmed $u Department of Neurology 2, Salpêtrière University Hospital, Assistance Public Hôpitaux de Paris, L'Université Pierre et Marie Curie University, Paris VI University, Paris, France.
- 700 1_
- $a Easaw, Jacob C $u Department of Medical Oncology, Cross Cancer Institute, Edmonton, California.
- 700 1_
- $a Kim, Chae-Yong $u Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Bundang, Korea.
- 700 1_
- $a Bruna, Jordi $u Department of Neurology, Hospital Universitari Bellvitge, Barcelona, Spain.
- 700 1_
- $a Hottinger, Andreas F $u Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
- 700 1_
- $a Kew, Yvonne $u Clinical Neuro-Oncology Research Program, Department of Internal Medicine, Methodist Hospital, Houston, Texas.
- 700 1_
- $a Roth, Patrick $u Department of Neurology, University of Zurich, Zurich, Switzerland.
- 700 1_
- $a Desai, Rajiv $u Neurosurgery and Spine Association, Maine Medical Center, Scarborough, Maine.
- 700 1_
- $a Villano, John L $u Clinical Neuro-Oncology Research Program, Department of Internal Medicine, University of Kentucky Medical Center, Lexington.
- 700 1_
- $a Kirson, Eilon D $u Research and Development, Novocure, Haifa, Switzerland.
- 700 1_
- $a Ram, Zvi $u Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Stupp, Roger $u Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Northwestern Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
- 773 0_
- $w MED00186178 $t JAMA oncology $x 2374-2445 $g Roč. 4, č. 4 (2018), s. 495-504
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29392280 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014111122 $b ABA008
- 999 __
- $a ok $b bmc $g 1452079 $s 1073969
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 4 $c 4 $d 495-504 $e 2018Apr01 $i 2374-2445 $m JAMA oncology $n JAMA Oncol $x MED00186178
- LZP __
- $a Pubmed-20191007
